Organization
Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy
111 abstracts
Abstract
Correlation between metastatic site and immunotherapy efficacy in patients with advanced dMMR/MSI colorectal cancer: Real-World Italian multicentric retrospective study (Colon-MSI).Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Medical Oncology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.Org: Fujian Cancer Hospital, First Chest Radiotherapy Department, Hunan Cancer Hospital, Changsha, China, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Department of Melanoma Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China, The Third People's Hospital of Zhengzhou,
Abstract
A single-arm exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.Org: Jiangsu Simcere Diagnostics Co., Ltd., Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Graduate School of Dalian Medical University,
Abstract
Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, AK Altona, Asklepios Tumourzentrum Hamburg, Oncolytics Biotech, Calgary, AB, Canada,
Abstract
Inhibition of AR and DNA-PK for radio-sensitization of AR-driven cancers.Org: Cancer Research UK Cambridge Institute, Artios Pharma, National Institutes of Health All of Us Research Program, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, AstraZeneca,
Abstract
A single institution review of immunotherapy use, adverse events, and outcomes in early-onset cancer.Org: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, University Hospitals Center for Clinical Research, Case Western Reserve University School of Medicine, University Hospitals Sussex NHS Foundation Trust,
Abstract
Counting coins and cardiovascular catastrophes: The income–pancreas connection.Org: Landmark Medical Center, New York Medical College - Saint Michael's Medical Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Mayo Clinic, Sheikh Shakhbout Medical City in Partnership With Mayo Clinic,
Abstract
Alleviating lung injury and pulmonary fibrosis in radiotherapy-immunotherapy combination: The role of low-dose radiation therapy.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Affiliated Hospital of Guizhou Medical University/Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China,
Abstract
Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC): A single-arm, open-label, phase II study.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,
Abstract
A cross-sectional study of synchronous liver metastasis in patients with gastric cancer.Org: Zhongda Hospital, Southeast University, Medical School of University, Southeast University, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Dalpiciclib and chidamide in patients with HR+/HER2- advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China,
Abstract
Survival outcomes for metastatic castration sensitive prostate cancer: Real world data from a Danish cohort 2016-2022.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark,
Abstract
Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada.Org: University of Calgary, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Princess Margaret Cancer Center, University Health Network, University of British Columbia,
Abstract
A propensity score–matched comparison of fruquintinib (FRU) versus FRU combined with PD-1 inhibitors for microsatellite stability (MSS) metastatic colorectal cancer: Real-world data.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Disparities in diagnosis and access to care in patients with young-onset rectal cancers in northeast Ohio.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Department of Surgery, Brigham and Women's Hospital, Boston, MA, University Hospitals Cleveland Medical Center,
Abstract
Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
PD-1 inhibitors versus conventional therapies for adjuvant treatment of resected acral melanoma: A systematic review and meta-analysis.Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Effect of GSDMD-mediated pyroptosis on the myocardial injury induced by PD-1 inhibitor combined with x-ray radiation.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Affiliated Hospital of Guizhou Medical University/Affiliated Cancer Hospital of Guizhou Medical University,
Abstract
Navigating the intersection: Exploring racial disparities in major cardiovascular and cerebrovascular events among patients with hepatocellular carcinoma.Org: Landmark Medical Center, Woonsocket, River 3 Renal, New York Medical College - Saint Michael's Medical Center, Valhalla,
Abstract
Preliminary results of a randomized controlled, open-label, multi-center phase II study of camrelizumab combined with chemotherapy followed by concurrent chemoradiotherapy and camrelizumab consolidation therapy versus standard chemoradiotherapy as first-line treatment for limited-disease small cell lung cancer.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shanghai Pulmonary Hospital, Shanghai, China, Tongji University School of Medicine, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Department of Pulmonary and Critical Care Medicine,
Abstract
Regorafenib Plus for third-line treatment in metastatic colorectal cancer: A real-world study.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Chaoyang Hospital, Capital Medical University,
Abstract
Enhancing the efficacy of anti-PD-L1 therapy by cabozantinib in the treatment of advanced esophageal squamous cell carcinoma (ESCC): Rationales from a preclinical study.Org: National Taiwan University Cancer Center/Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch,
Abstract
Association between psychological distress and treatment efficacy in patients with newly diagnosed SCLC.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Second Xiangya Hospital of Central South University, Central South University, Changsha, China,
Abstract
Predictive value of positive lymph node ratio in patients with locally advanced gastric remnant cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Renji Hospital Shanghai Jiaotong University School of Medicine, School of Medicine, Zhejiang University, Hangzhou, China, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Efficacy and safety of PD-1 inhibitors plus metronomic oral vinorelbine in elderly pre-treated patients with metastatic non-small-cell lung cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
An open-label, placebo-controlled, randomized phase II trial of camrelizumab combined with or without apatinib or capecitabine in the treatment of previously treated advanced pancreatic cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fudan University Shanghai Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine,
Abstract
Trophoblast cell-surface antigen 2 is a biomarker and potential therapeutic target in human colon cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Phase I safety and preliminary efficacy of PM1009, a bispecific antibody targeting TIGIT and PVRIG, in patients with advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.Org: Institut du Cancer Paris CARPEM, APHP-INSERM U1149 Universite Paris Diderot, Digestive Oncology Department, APHP.Centre - Université Paris Cité, Hôpital Européeen G. Pompidou,
Abstract
Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Yunnan Cancer Hospital, Kunming, Yunnan, China, Anhui Chest Hospital,
Abstract
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).Org: Erasmus MC Cancer Center, Rotterdam, Netherlands Cancer Institute, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Fondazione IRCCS Istituto Neurologico Carlo Besta,
Abstract
Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).Org: PDS Biotechnology, Merck & Co., Inc., Lineberger Comprehensive Cancer Center, University of Michigan Health System Comprehensive Cancer Center, MUSC Hollings Cancer Center, Charleston, SC,
Abstract
Comprehensive study of the intratumoral microbiome in early- vs. late-onset colorectal cancer: Final analysis of COSMO CRC.Org: Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Remote delivery of a mindfulness-based intervention to decrease stress levels and promote coping among health-care workers during the COVID-19 pandemic.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Western University, University College Cork, Cork University Hospital Group, Biostatistic Department,
Abstract
Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.Org: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Affiliated Dongguan Hospital, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital,
Abstract
The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study.Org: Vanderbilt-Ingram Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, University of Texas MD Anderson Cancer Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV - IRCCS,
Abstract
Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.Org: Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.Org: Aix-Marseille University CHU Timone, APHM, Service d'Oncologie Multidisciplinaire & Innovations Thérapeutiques, CNRS UMR 5309-INSERM U1209, INP, Inst Neurophysiopathol,
Abstract
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China,
Abstract
Investigation of synthetic lethality gene pairs in the DNA damage response pathway in response to immunotherapy in pan-cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Shijitan Hospital, Capital Medical University, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., 3D Medicine Inc.,
Abstract
A 5-hydroxymethylcytosine-based noninvasive model for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma: The METHOD-2 study.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd., Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, The First Medical Center,
Abstract
Multisystem immune-related adverse events from dual agent immunotherapy use.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario Institute for Cancer Research, Toronto, ON, Canada, Oncotelic,
Abstract
Understanding resistance in V600E BRAF advanced colon cancer treated with BRAF inhibitors plus anti-EGFR antibodies +/- MEK inhibitors: The URBAN study.Org: Medical Oncology 1, Venetian Institute of Oncology-IRCCS, Padua, Padua, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy, Department of Medicine (DIMED) University of Padua and Veneto Institute of Oncology (IOV-IRCCS ),
Abstract
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Eastern Hepatobiliary Surgery Hospital, Shanghai Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Active bone marrow-sparing to reduce the incidence of grade 3+ acute hematologic toxicity in patients with locally advanced cervical cancer who receive chemoradiotherapy: A single-center prospective randomized controlled trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, the Second People's Hospital of Yibin City, Laboratory Medicine Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, The Second Hospital of Yibin City,
Abstract
Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results.Org: Legorreta Cancer Center, Brown University - Lifespan Cancer Institute, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Clinical Research Institute at Rambam, Rambam Medical Center,
Abstract
Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.Org: Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Exploring HER2-low disease: Does it impact breast cancer survival?Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Catalan Institute of Oncology-Hospitalet, B-ARGO (Badalona Applied Research Group in Oncology), IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona,
Abstract
Dacomitinib for patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations: Do mutation patterns matter?Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.Org: SOLTI Cancer Research Group, Ohio State University Comprehensive Cancer Center, Novartis Pharmaceuticals, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, University of North Carolina School of Medicine,
Abstract
Circulating tumor DNA in plasma as an early predictor for pathological lymph node involvement and (neo-)adjuvant chemotherapy in patients with colon cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Danish Colorectal Cancer Center South, Vejle Hospital, University Hospital of Southern Denmark, Institute of Regional Health Research,
Abstract
Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial).Org: Gothenburg University, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital,
Abstract
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).Org: Mayo Clinic, Division of Biomedical Statistics and Informatics, Mayo Clinic Florida, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Department of Quantitative Science Research,
Abstract
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).Org: Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Rogel Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Bashkir State Medical University,
Abstract
Relation between circulating biomarkers at diagnosis of early luminal-like breast cancer and subsequent risk of distant metastases.Org: Laboratory of Experimental Oncology (LEO), Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Laboratory of Cell Stress & Immunity (CSI), Department of Cellular and Molecular Medicine, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study.Org: University Hospitals Leuven, Leuven, Belgium, VIB Center for Cancer Biology, University of Leuven, KU Leuven, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).Org: Sun Yat-sen University Cancer Center (China), Guangzhou, No, China National Biotec Group, Shanghai East Hospital, Tongji University, Shanghai, China, Tongji University School of Medicine,
Abstract
Tislelizumab plus chemotherapy in patients with advanced brain metastases of non-squamous non-small cell lung cancer: A multicenter, prospective, open-label phase 2 study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China,
Abstract
Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shengjing Hospital of China Medical University, Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, The First Affiliated Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China,
Abstract
Soluble urokinase-type plasminogen activator receptor, suPAR, as a prognostic biomarker in advanced pancreatic cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Experimental Cancer Therapy Unit, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Copenhagen University Hospital, Herlev Gentofte Hospital,
Abstract
Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Tongji Medical College Huazhong University of Science and Technology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, College of Biomedicine and Health,
Abstract
Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).Org: Schulich School of Medicine and Dentistry, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, London Regional Cancer Program, University Health Network,
Abstract
PVR expression in tumor microenvironment of advanced hepatocellular carcinoma.Org: National Taiwan University Hospital Yunlin Branch, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Cancer Center/Hospital,
Abstract
A decision-making tool for first-line treatment in advanced non–small-cell lung cancer based on plasma proteome biomarkers.Org: OncoHost LTD, Heidelberg University Hospital, Heidelberg, Germany, Roswell Park Cancer Institute, Sheba Medical Center, Or-Yeuda, Rambam Health Care,
Abstract
Extracellular mechanical forces and ferroptosis in triple negative breast cancer (TNBC): Targeting of aurora kinase A (AURKA).Org: Fudan University Shanghai Cancer Center, Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shanghai Medical College, Fudan University,
Abstract
Tp53 as a potential therapeutic biomarker in patients with recurrent high-grade glioma treated with anlotinib and temozolomide.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Henan Provincial People's Hospital and People's Hospital of Henan University, People's Hospital of Henan University, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University,
Abstract
A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM 2 trial).Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, University of Gothenburg, Gothenburg, Sweden,
Abstract
The prognostic impact of NKA dynamics in first-line treatment of metastatic colorectal cancer.Org: Department of Biochemistry & Immunology, Danish Colorectal Cancer Center South, Institute of Regional Health Research, University Hospital of Southern Denmark, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
A comparison between a clinical decision support system and clinicians with guidelines in breast cancer.Org: Fifth Medical Center of PLA General Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Affiliated Hospital of Hebei University, Baoding, China, Fourth Affiliated Hospital of Hebei Medical University,
Abstract
Preliminary efficacy and safety of camrelizumab plus metronomic oral vinorelbine as first-line therapy for people aged 70 and above with advanced non-small cell lung cancer (NSCLC) from a phase II trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Beijing Hospital of Traditional Chinese Medicine,
Abstract
Potential therapeutic implications of next generation sequencing (NGS)-based molecular profiling in HR+/HER2- metastatic breast cancer (mBC).Org: Medical Oncology Group, Azienda Ospedaliera Universitaria Integrata Verona, Medical Surgeon, Section of Breast Surgery, Department of Diagnostics and Public Health,
Abstract
Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS).Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch, Graduate Institute Of Oncology NTU College of Medicine, National Health Research Institutes, National Taiwan University Cancer Center/Hospital,
Abstract
Preclinical evidence for synergistic effects of autophagy inhibitor and alpelisib in PI3KCA mutated non-small cell lung cancer: Implications for future clinical trials.Org: The Catholic University of Korea, St. Vincent's Hospital, St Vincents Hospital/The Catholic University of Korea, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Use of antibiotics and outcomes of patients presenting to emergency department with non-neutropenic fever and/or suspected infection.Org: Juravinski Hospital and Cancer Centre, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Juravinski Cancer Centre, Michael G. DeGroote School of Medicine, Juravinski Cancer Inst,
Abstract
Pattern of failure and re-irradiation for stereotactic radiotherapy treated brain metastases from non-small cell lung cancer (NSCLC).Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Fudan University Shanghai Cancer Center,
Abstract
BORTEM-17: A phase IB/II single arm, multicentre study investigating the efficacy of sequential bortezomib and temozolomide in recurrent GBM with unmethylated MGMT promoter—The results of an interim analysis.Org: Haukeland University Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Bergen, Norway, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway,
Abstract
A phase 2 study of modified chemotherapy plus pembrolizumab as perioperative therapy for stage II/IIIA esophageal squamous cell carcinoma.Org: The First Medical Center of PLA General Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, General Hospital of Chinese PLA, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Chinese PLA General Hospital,
Abstract
Atypical response patterns in Chinese patients with cancer with immune checkpoint blockade.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital with Shandong First Medical University, Jinan, China,
Abstract
Safety and efficacy exploration of intraperitoneal perfusion of PD-1 monoclonal antibody for patients with primary liver cancer with malignant ascites: A prospective, single-arm, phase Ib clinical trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing Medical University, Research Institute of General Surgery, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Abstract
A retrospective study on the efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in gastrointestinal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma,
Abstract
ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.Org: University Hospitals Leuven, Leuven, Belgium, Leuven Cancer Institute, BGOG, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Copenhagen University Hospital,
Abstract
Comprehensive molecular profiling from liquid and tissue for analysing the somatic mutational landscape in an Indian breast cancer cohort.Org: Fortis Cancer Institute, Sir H N Reliance Foundation Hospital and Research Centre, BALCO Medical Center, Fortis Hospital Mulund, Datar Cancer Genetics,
Abstract
Prognosis factors for long-term eribulin response in a cohort of patients with HER2-negative metastatic breast cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, CHU Besançon, Besançon, Department of medical onclogy, Peking Union Medical College Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,
Abstract
Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced esophageal cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shanghai East Hospital, Tongji University, Shanghai, China, Tongji Universtity School of Medicine,
Abstract
Racial disparities in the outcomes of allogeneic bone marrow transplant: A 5-year nationwide inpatient study.Org: Albert Einstein College of Medicine, Jacobi Medical Center/North Central Bronx, Springfield Memorial Hospital, SIU School of Medicine, Montefiore Medical Center,
Abstract
The smart options of induction therapy for locally advanced betel-nuts related HNSCC in Taiwan.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan Bio Therapeutics, Yun-lin Branch,
Abstract
Multi-omics analysis to reveal the change of peripheral blood TCR repertoire and tumor burden during neoadjuvant chemotherapy combined with sequential PD-1 blockade for patients with non-small cell lung cancers: A single-center, single-arm phase 2 trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Chinese PLA General Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, School of Medicine Nankai University,
Abstract
Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: The experience of an academic hospital.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Antwerp University Hospital, University Hospital of Antwerp, Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium,
Abstract
Use of direct oral anticoagulants (DOACs) in oncology: A phase IV study on impact of edoxaban treatment in Italian patients with cancer with venous thromboembolism during antineoplastic therapy (EDOI trial, GOIRC 05-2018).Org: IRCCS AUSL Reggio Emilia, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, University of Turin at Ordine Mauriziano Hospital, Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland,
Abstract
Financial toxicity of hematologic malignancy therapies: Subjective experience of patients and impact on access to care.Org: Montefiore Medical Center, Albert Einstein College of Medicine, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Bronx, NY, Montefiore Medical Center Wakefield Campus,
Abstract
Capturing age-related changes in the tumor microenvironment of luminal breast cancer using the multiplex immunohistochemistry technique, MILAN.Org: Laboratory of Experimental Oncology (LEO), Laboratory for Translational Cell and Tissue Research, Multidisciplinary Breast Center, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, University Hospitals Leuven, Leuven, Belgium,
Abstract
Locoregional plus systemic therapy for unresectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis.Org: Affiliated Hospital of Qingdao University, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Department of Interventional medicine,The Affiliated Hospital of Qingdao University, Qingdao, China,
Abstract
ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China, Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China, Department of Breast Cancer, the Fifth Medical Center Affiliated to PLA General Hospital, Beijing, China,
Abstract
Gut microbiota profiling and clinical response in patients with metastatic non-small cell lung cancer receiving endothelial growth factor-tyrosine kinase inhibitors (EGFR-TKI).Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital,
Abstract
Immunotherapy combined with rh-endostatin improved clinical outcomes over ICIs plus chemotherapy for second-line treatment of advanced NSCLC.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China.,
Abstract
Characteristics and trends of globally registered malignant pleural mesothelioma clinical trials in the past 27 years.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China, Guangdong Provincial People's Hospital,
Abstract
A phase Ⅰ/Ⅱa study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study.Org: Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Provincial Hospital of Chinese Medicine Breast Center, Guangdong Provincial People's Hospital,
Abstract
Effects of different immune microenvironment characteristics on effect of immune checkpoint inhibitors in solid tumors with TGFBR2 mutation.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Huashan Hospital Fudan University, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Association of ethnicity with overall survival in patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma Org: Jacobi Medical Center/Albert Einstein College of Medicine, Universal College of Medical Sciences, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, UCSF Helen Diller Family Comp Cancer Ctr, Albert Einstein College of Medicine,
Abstract
Efficacy and safety of immunonutrition in preventing oral mucositis during concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital of University of South China,
Abstract
Comparison of clinical outcomes in patients with advanced pulmonary sarcomatoid carcinoma treated with immunotherapy-based regimen or chemotherapy: A study based on the SEER database and multicentric real-world settings.Org: The Second Affiliated Hospital Of Nanchang University, Nanchang second affiliated hospital, Second Affiliated Hospital of Nanchang University, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
From seed to harvest: 18-month experience of molecular tumor board (MTB)-based precision oncology practice at the Verona University Hospital.Org: Medical Oncology Group, Azienda Ospedaliera Universitaria Integrata di Verona, ARC-Net Research Centre - Diagnostic and Public Health Department, University of Verona - Faculty of Medicine, Department of Diagnostics and Public Health,
Abstract
Efficacy of immunotherapy in MSI metastatic colorectal cancer patients: A Real-World Italian multicentric retrospective study (Colon-MSI Study).Org: Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliero-Universitaria Pisana, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis.Org: Albert Einstein College of Medicine, Jacobi Medical Center/North Central Bronx, Bronx, NY, Albert Einstein College of Medicine - Montefiore Medical Center, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Integrating radiation therapy with CDK4/6 inhibitors for breast cancer: A systematic review and meta-analysis of toxicity.Org: Azienda Ospedaliera Universitaria Careggi, University of Florence, AOUC, CyberKnife Center, Istituto Fiorentino di Cura e Assistenza (IFCA), The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
Abstract
Therapeutic effects of combination with EGFR-TKIs and radiotherapy on the prognosis of stage IV lung adenocarcinomas harboring 19-Del or 21-L858R: A retrospective study.Org: Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Jinan, China, Department of oncology, Shengli Oilfield Central Hospital,
Abstract
Blood eosinophils as prognostic biomarkers for advanced urothelial carcinoma in patients treated with avelumab: First results of the MALVA study (Meet-URO 25).Org: Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, Careggi University Hospital, Florence, Italy, Istituto Oncologico Veneto, IOV-RCCS, Padova, Italy, Ospedale A.R.N.A.S Civico,